Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610273 | 0.71 | ALDH1A1 (0.32) | LMNACYP2C9MAPT | |
| SCHEMBL6238926 | 0.71 | ALDH1A1 (0.32) | LMNACYP2C9MAPT | |
| SCHEMBL9050637 | 0.68 | LMNA (0.32) | MEN1KMT2ALMNACYP2C9MAPT | |
| SCHEMBL1108532 | 0.64 | CA1 (0.39) | KMT2ATSHRMAPT | |
| SCHEMBL1108536 | 0.64 | CA1 (0.39) | KMT2ATSHRMAPT | |
| SCHEMBL23354085 | 0.63 | ADAMTS5 (0.40) | MEN1KMT2A | |
| SCHEMBL4861780 | 0.63 | MEN1 (0.38) | MEN1KMT2ALMNATSHR | |
| SCHEMBL2872028 | 0.63 | — | — | |
| SCHEMBL6839992 | 0.63 | GAA (0.45) | CYP2C9MAPT | |
| Urethane SCHEMBL1880681 | 0.62 | ALOX15 (0.52) | MEN1KMT2ALMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MEN1 2122/4885KMT2A 2545/4885LMNA 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.